U.S. Markets closed

CTMX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytomX Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 14, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CytomX Therapeutics, Inc. ("CytomX" or "the Company") (CTMX). Investors who purchased CytomX securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ctmx.

The investigation concerns whether CytomX and certain of its officers and/or directors have violated federal securities laws.

On May 13, 2020, CytomX made available abstracts for the Company's clinical presentations for CX-072, an PD-L1 inhibitor, and CX-2009, an antibody-drug conjugate. Results from CytomX's Phase 2 study evaluating CX-072 in patients with solid tumors showed a response rate of 8.8%, compared to a response rate of 18.5% in patients receiving the combination of CX-072 and Bristol Myers Squibb's Yervoy (ipilimumab). Meanwhile, results from CytomX's Phase 1/2 study evaluating CX-2009 in patients with solid tumors showed "evidence" of clinical activity at doses at least 4 mg/kg 3x/week, yet the data suggest a significantly higher rate of serious or greater treatment-related toxicity to the eyes at dose equivalents at least 8 mg/kg 3x/week. Following the release of the foregoing data, CytomX's stock price fell sharply during intraday trading on May 14, 2020.

If you are aware of any facts relating to this investigation or purchased CytomX shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/ctmx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

View source version on accesswire.com: